Immunological Response of Bladder Cancer Patients Under BCG

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

May 24, 2024

Study Completion Date

August 18, 2024

Conditions
Bladder CancerBacillus Calmette-Guerin
Interventions
BIOLOGICAL

Bacillus Calmette Guerin

0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.

OTHER

PLACEBO

0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.

Trial Locations (2)

13034685

Pontifical Catholic University of Campinas Hospital, Campinas

13083887

Hospital das Clínicas Unicamp, Campinas

All Listed Sponsors
collaborator

Coordination for the Improvement of Higher Education Personnel

OTHER

collaborator

Pontifical University Catholic of Campinas

OTHER

lead

University of Campinas, Brazil

OTHER

NCT04806178 - Immunological Response of Bladder Cancer Patients Under BCG | Biotech Hunter | Biotech Hunter